Inhibition of PDE5 has been validated to enhance cGMP levels in specific tissues and benefit patients with various diseases such as male erectile dysfunction and pulmonary arterial hypertension [15,16,17]. Here, PDE5A is linked to pulmonary arterial hypertension.